Really important stage shift shown in Taiwan National Lung screen program. Bravo Dr PC Yang! Family hx is a key risk factor. Excited to collaborate with Allison Chang and Jill Feldman to open a clinical trial soon focused on screening in those w/ a positive family hx #ASCO24

Happening NOW: Lung cancer poster sessions here at #ASCO24 Arthi Sridhar presents her retrospective study from Mayo Clinic evaluating the clinical outcomes of patients w/ unresectable NSCLC s/p induction chemoIO. So very proud of her!! ASCO

Proud of our faculty to be Arthi Sridhar presenting a poster at #asco24. UTSW Simmons Cancer Center

A few more highlights from Mayo fellows at #ASCO24! Arthi Sridhar @Aditisinghlove

Lucky to work with Arthi Sridhar and grateful for the leadership of Martina Murphy, MD who tirelessly empowers and fosters the growth of her team IMG Oncologists Women in Oncology Hematology & Oncology Women Physicians Group—HOWPG

So inspired by these women - their tenacity, their intelligence & their passion is second to none. Their impact on the field of #oncology and those around them will leave an important mark! I’m so lucky to get to know and work with them! IMG Oncologists Hematology & Oncology Women Physicians Group—HOWPG

Thank you Tian Zhang, MD, MHS and SawsanRashdanMD! Excited to join the team at UTSW Hematology & Oncology #ASCO24

Also think there needs to be training in oncology on managing countertransference. So many family meetings this year where outside in the pre-meet we decide no more treatment is being offered and that changes to ‘we can try x’ in the room when emotions are high. We’re all human.

IMPORTANT: the states allowing #IMGs to practice without residency requirements thematchguy.com/state-img-lice…

Amazing Fumiko Ladd Chino, MD, FASCO !!!

Very cool trial in JAMA Oncology! Pts w/ lung cancer on TKIs AND who got consolidation XRT AND had no cancer on imaging, ctDNA, or CEA ➡️ split into two groups A) stop TKI or B) continue TKI. Similar outcomes. #LCSM Chat OncoAlert EGFR Resisters ALK Positive The ROS1ders, Inc.

Vorasidenib now FDA Oncology approved based off Ph3 #INDIGO for residual/recurrent Gr 2 Astrocytoma/Oligodendroglioma w/ IDH1/2 mutation! -mPFS, 27.7mos vs. 11.1mos (HR: 0.39) - Time to next intervention was significantly improved - Gr ≥ 3 AEs 22.8% #OncTwitter #NeuroOnc

Grateful for the incredible mentors I’ve had at every stage. Collaborated with ASCO TECAG colleagues to write about the many facets of mentorship. Hope it brings insights into this often overlooked part of our professional journey. Dawood Findakly MD Dionisia Quiroga, DO, PhD Arthi Sridhar 1)

FYI #MedTwitter #OncTwitter #lcsm I am leading a course called “Unlocking the Potential of Breakthroughs in #NSCLC Therapeutic Approaches” that offers CME/CE credit. Would love to have you! You can learn more and sign up at: provaeducation.gathered.com/invitation?ref…

All you need to know about mentorship: a collaborative effort by ASCO TECAG oncodaily.com/blog/125051 Fionnuala Crowley Dawood Findakly MD Dionisia Quiroga, DO, PhD Arthi Sridhar Fawzi Abu Rous, MD Anusha MD Logan Roof, MD Reviewer 2 Rajat Thawani #Cancer #ASCOTECAG #Mentorship #OncoDaily #Oncology

1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇

Our editorial on CHOICE-01 trial highlights data on Toripalimab the several FDA Oncology approved ICI 💊 for mNSCLC. However, “me too” drugs in this space has been highlighted by many and cannot be ignored. Access to ICIs continue to be limited 🌎 Eric K. Singhi, MD IMG Oncologists

#WCLC24 may be over but the educational material continues In this Spanish episode we discuss the novel studies presented at the conference for our colleagues in LATAM Thank you IASLC for the invitation to host and rossana ruiz and Maria Antonia Vélez for being such insightful guests

🔥🚨OncoAlert Hot off the press. U.S. FDA approves #Pembrolizumab plus #Chemothetapy (#Platinum + #Pemetrexed) for 1st line #Treatment of advanced unresectable #Pleural #Mesothelioma. Approval based on #Keynote 483 study: ✅⬆️#OS: HR: 0.79 👇🏼 shorturl.at/ukg4P

Thank you FOX 13 News Utah for having me on to discuss all things breast cancer and caring for the Latina women of Utah. Get screened! fox13now.com/the-place/brea…